International Journal of Heart Failure最新文献

{"title":"Is Atrial Fibrillation Ablation Really Beneficial in Patients with Heart Failure?","authors":"Jin-Bae Kim, Youngshin Lee","doi":"10.36628/ijhf.2021.0030","DOIUrl":"10.36628/ijhf.2021.0030","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"197-199"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/4c/ijhf-3-197.PMC9536654.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40668608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Big Data to Understand Rare Diseases.","authors":"Jun-Bean Park","doi":"10.36628/ijhf.2021.0026","DOIUrl":"10.36628/ijhf.2021.0026","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"194-196"},"PeriodicalIF":0.0,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/42/ijhf-3-194.PMC9536653.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40557213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, Cause of Death, and Survival of Amyloidosis in Korea: A Retrospective Population-Based Study.","authors":"Shin Yi Jang,&nbsp;Darae Kim,&nbsp;Jin-Oh Choi,&nbsp;Eun-Seok Jeon","doi":"10.36628/ijhf.2021.0006","DOIUrl":"https://doi.org/10.36628/ijhf.2021.0006","url":null,"abstract":"<p><strong>Background and objectives: </strong>We sought to assess incidence, cause of death, and survival for amyloidosis. We acquired amyloidosis data from the National Health Insurance Service in Korea from 2006 through 2017 (n=2,233; male 53.5%).</p><p><strong>Methods: </strong>We calculated the age-standardized incidence rate, analyzed the survival rate (SR) using the Kaplan-Meier method, and analyzed the death risk using Cox proportional hazards methods.</p><p><strong>Results: </strong>The mean age was 57.0±16.7 years in males and 56.8±15.6 years in females (p=0.795). The proportion of death was 34.7%. The causes of death were endocrine, nutritional, and metabolic diseases (33.9%), malignant neoplasm (20.8%), and diseases of the circulatory system (9.68%). The overall age-standardized incidence rate was 0.47 persons per 100,000 persons in 2017. Overall, the 10-year SR for amyloidosis was 57.7%. Adjusted hazard ratios were 9.16 among 40s', 16.1 among 50s', 30.3 among 60s', 48.7 among 70s', 80.1 among people 80 years or older, and 1.21 in the medium-level socioeconomic position group.</p><p><strong>Conclusions: </strong>The age-standardized incidence rate of amyloidosis was about 0.5 persons per 100,000 persons in 2017. The 10-year SR of amyloidosis was about 58%. The most common cause of death was endocrine, nutritional, and metabolic diseases. The risk of death from amyloidosis increased with age and medium socioeconomic position.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"172-178"},"PeriodicalIF":0.0,"publicationDate":"2021-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/5e/ijhf-3-172.PMC9536655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40557212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhythm Control of Persistent Atrial Fibrillation in Systolic Heart Failure: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.","authors":"Dibbendhu Khanra,&nbsp;Saurabh Deshpande,&nbsp;Anindya Mukherjee,&nbsp;Siddhratha Mohan,&nbsp;Hassan Khan,&nbsp;Sanjeev Kathuria,&nbsp;Danesh Kella,&nbsp;Deepak Padmanabhan","doi":"10.36628/ijhf.2021.0008","DOIUrl":"https://doi.org/10.36628/ijhf.2021.0008","url":null,"abstract":"<p><strong>Background and objectives: </strong>Persistent atrial fibrillation (PeAF) with heart failure (HF) arguably constitutes the sickest subset of atrial fibrillation (AF) patients.</p><p><strong>Methods: </strong>A systematic search was made in PubMed, Embase, and Scopus databases. Network meta-analysis (NMA) of PeAF patients with systolic HF comparing all-cause mortality, change in HF-related quality of life (QoL) and hospitalization due to heart failure (HHF) were performed among catheter ablation (CA) of AF, rate-controlling drugs (RCDs), anti-arrhythmic drugs (AADs), and atrio-ventricular nodal ablation (AVNA) using Bayesian random effect model.</p><p><strong>Results: </strong>Ablation strategies resulted significantly lower mortality than medical therapies (odds ratio [OR], 0.51; 95% confidence interval [CI], 0.35 to 0.76). CA of AF was associated with lower trend of mortality (OR, 0.78; 95% credible interval [CrI], 0.08 to 7.63) in comparison to AVNA in the Bayesian NMA. Rhythm control strategies resulted significantly higher improvement of QoL than rate control strategies (mean difference [MD], -12.78; 95% CI, -21.26 to -4.31). Bayesian NMA showed that CA of AF was better than AAD (MD, -7.98; 95% CrI, -27.68 to 8.27), however ranked AVNA to be lowest. Ablation strategies provided significantly lower HHF than medical therapies (OR, 0.42; 95% CI, 0.30 to 0.58). Bayesian NMA showed that CA of AF performed not only better than AAD (OR, 0.33; 95% CrI, 0.09 to 1.3) to reduce HHF, but also than AVNA (OR, 0.20; 95% CrI, 0.00 to 4.76). Of note, RCD ranked lowest with regard to mortality and HHF.</p><p><strong>Conclusions: </strong>CA of AF remains the best strategy even for the sickest group of PeAF patients with systolic HF in regards to all-cause mortality, HF-related QoL and HHF.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"179-193"},"PeriodicalIF":0.0,"publicationDate":"2021-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/25/ijhf-3-179.PMC9536657.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40668606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom.","authors":"Petar M Seferovic,&nbsp;Marija Polovina,&nbsp;Ivan Milinkovic,&nbsp;Stefan Anker,&nbsp;Giuseppe Rosano,&nbsp;Andrew Coats","doi":"10.36628/ijhf.2021.0013","DOIUrl":"https://doi.org/10.36628/ijhf.2021.0013","url":null,"abstract":"<p><p>Over the past three decades, pharmacological treatment of heart failure (HF) with reduced ejection fraction (HFrEF) has witnessed a significant progress with the introduction of multiple disease-modifying therapies with a proven benefit on morbidity, mortality and quality of life. Recently, several novel medications (sacubitril/valsartan, sodium-glucose contransporter-2 [SGLT2] inhibitors, vericiguat and omecamtiv mecarbil) have shown to provide further improvement in outcomes in patients already receiving standard therapy for HFrEF. Available evidence suggests that sacubitril/valsartan and SGLT2 inhibitors (dapagliflozin and empagliflozin) are beneficial and well-tolerated in the majority inpatients and could be the mainstay treatment of HFrEF. Another group of medications (vericiguat and omecamtiv mecarbil) has shown promising results in reducing the risk of the composite of HF hospitalisation or cardiovascular mortality in patients with the more severe or advanced HF requiring recent hospitalisation. Therefore, these medications may be considered for the treatment of select group of patients with HFrEF with persisting or worsening symptoms despite optimal treatment. In addition, advances in pharmacological management of comorbidities frequently seen in HFrEF patients (diabetes, iron deficiency/anaemia, hyperkalaemia) provide further opportunities to improve outcomes. Given the increasing complexity of evidence-based therapies for HFrEF, there is a growing need to provide a practical perspective to their use. The purpose of this review is to summarise scientific evidence on the efficacy and safety of new and emerging medical therapies in HFrEF, with a focus on the clinical perspective of their use.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 4","pages":"205-218"},"PeriodicalIF":0.0,"publicationDate":"2021-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/9e/ijhf-3-205.PMC9536688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40668600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Post-Myocardial Infarction Ventricular Septal Rupture.","authors":"Jin-Eun Song,&nbsp;Yun Seok Kim,&nbsp;In-Cheol Kim","doi":"10.36628/ijhf.2021.0004","DOIUrl":"https://doi.org/10.36628/ijhf.2021.0004","url":null,"abstract":"https://e-heartfailure.org A 61-year-old man with no previous history visited the emergency room due to a sudden onset of chest pains since 2 days. Initial electrocardiography (ECG) showed a 15 mm ST segment elevation in precordial leads with pathologic Q waves (Figure 1A). Initial supine anteroposterior chest radiography showed cardiomegaly (cardiothoracic ratio 0.56) with pulmonary congestion (Figure 1B). Since the patient presented with hypotension (blood pressure: 78/62 mmHg) and persistent chest pain, emergency percutaneous coronary intervention was planned under the support of norepinephrine (0.1 μg/kg/min). The initial coronary angiography revealed total occlusion of the middle left anterior descending (LAD) artery (Supplementary Video 1). After successful implantation of a sirolimus-eluting stent (3×24 mm), angiography showed no-reflow phenomenon (Supplementary Video 2). Intracoronary nicorandil infusion and intravascular abciximab were administered, and TIMI flow of grade 1 was confirmed by follow-up angiography (Supplementary Video 3). Postprocedural ECG showed partially resolved ST segments, but abnormal Q waves persisted (Figure 1C). Laboratory findings revealed the following: creatine kinase-myocardial band, 110 ng/mL; Troponin I 59.4 ng/mL; lactic acid, 4.4 mmol/L; and total bilirubin, 1.63 mg/ dL. Transthoracic echocardiography (TTE) showed severely decreased left ventricular (LV) ejection fraction with akinesia of the anterior and septal walls and aneurysm formation of the apical wall. Color Doppler imaging revealed shunt flow at the apical portion of the interventricular septum due to ventricular septal rupture (VSR) (1.6 cm) (Figure 1E). Since the patient's pain was tolerable, and his vital signs and laboratory findings were stabilized without increment of positive inotropes (norepinephrine 0.1 μg/kg/min), our multidisciplinary cardiac team including a cardiac intensivist, cardiac surgeon, and cardiac imaging specialist, decided to delay surgery and closely monitor the patient at the cardiac intensive care unit. On the ninth day following admission, the patient reported worsening dyspnea. Chest radiography showed abrupt exacerbation of bilateral pulmonary edema and systolic blood pressure dropped under 90 mmHg, requiring additional norepinephrine infusion to 0.15 μg/kg/min (Figure 1D). Immediate extracorporeal membrane oxygenation (ECMO) was performed with mechanical ventilator support (Flow rate 3.8 liter per minute [LPM], 3565 revolution per minute [RPM], FiO2 0.65). Chest radiography confirmed the resolution of pulmonary edema. The patient's vital signs and laboratory findings were stabilized. However, on the sixth day of ECMO, lactic acid and bilirubin level increased to 6.5 mmol/L and 5.63 mg/dL, respectively, indicating progression of inadequate tissue perfusion and venous congestion despite the ECMO support. Conservative management such as diuretics and ursodeoxycholic acid use was not effective. Therefore, the heart team","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"200-204"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/3d/ijhf-3-200.PMC9536656.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40668609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary Hypertension in Heart Failure.","authors":"Albert Youngwoo Jang, Su Jung Park, Wook-Jin Chung","doi":"10.36628/ijhf.2020.0053","DOIUrl":"10.36628/ijhf.2020.0053","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) is traditionally defined as a mean pulmonary arterial pressure (mPAP) ≥25 mmHg. Although various factors cause PH, the most common etiology is PH due to left heart disease (PH-LHD). The underlying LHD is characterized by heart failure (HF) with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), valvular heart disease, cardiomyopathies, or arrhythmic diseases. Regardless of its underlying cause, elevated left atrial (LA) filling pressure is a manifestation of advanced heart disease. High LA pressure then causes persistent backflow to the pulmonary veins, which increases mPAP. PH-LHD at this stage is named isolated postcapillary PH (IpcPH). Further progression of IpcPH is associated with pulmonary vasculature remodeling and hypertrophy, which consists of adding the precapillary component of PH to the pre-existing postcapillary PH. This form of PH-LHD is called combined precapillary and postcapillary PH (CpcPH). To date, therapeutic strategies for PH-LHD have been investigated in the context of HFrEF or HFpEF. Pulmonary arterial hypertension (PAH)-specific drugs have been tested in HFrEF and HFpEF populations, although encouraging results have not been demonstrated. As PAH-specific drugs target the precapillary component of PH-LHD, future studies utilizing such therapeutics in PH-LHD patients with CpcPH appear to have a more robust pathobiological basis. This article reviews the diagnosis, pathophysiology, treatment, and future direction of PH in HF.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 3","pages":"147-159"},"PeriodicalIF":0.0,"publicationDate":"2021-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1b/18/ijhf-3-147.PMC9536651.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40557214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worsening Renal Function during Acute Decompensated Heart Failure: A Bad Signal Never to Ignore.","authors":"Sang-Hyeon Park, Jeehoon Kang","doi":"10.36628/ijhf.2021.0016","DOIUrl":"10.36628/ijhf.2021.0016","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 2","pages":"121-124"},"PeriodicalIF":0.0,"publicationDate":"2021-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/c9/ijhf-3-121.PMC9536693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40656684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of COVID-19 on Heart Failure: What Happened to the Patients with Heart Failure Who Could Not Visit Our Clinic Amid the COVID-19 Pandemic?","authors":"Dong-Hyuk Cho","doi":"10.36628/ijhf.2021.0014","DOIUrl":"10.36628/ijhf.2021.0014","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 2","pages":"125-127"},"PeriodicalIF":0.0,"publicationDate":"2021-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/1a/ijhf-3-125.PMC9536690.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40656686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ST2 as a Biomarker to Show the Preventive Effect of Exercise in Myocardial Injury by Doxorubicin?","authors":"Jieun Lee, Eung Ju Kim","doi":"10.36628/ijhf.2021.0003","DOIUrl":"10.36628/ijhf.2021.0003","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"3 2","pages":"117-120"},"PeriodicalIF":0.0,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/1c/ijhf-3-117.PMC9536689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40656683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}